SMC2 and colorectal cancer: Of note, SMC2 has been found to be over-expressed in a significant number of patients with colorectal cancer, gastric cancer, lymphoma and some types of neuroblastoma [19,20], and has been suggested as a risk biomarker in pancreatic cancers [21].